A Single-center, Open-label, Single-arm Phase Ib Clinical Study to Evaluate the Pharmacokinetics and Pharmacodynamic Characteristics of SHR-2017 Injection in Patients With Bone Metastases
Latest Information Update: 11 Jun 2024
At a glance
- Drugs SHR-2017 (Primary)
- Indications Bone metastases; Solid tumours
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 06 Jun 2024 Status changed from not yet recruiting to recruiting.
- 26 Apr 2024 New trial record